Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 6/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | GRM8 | O00222 | 2/20 | 0.45 |
| ▸ | GRM6 | O15303 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 4/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | LIG1 | P18858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2053552 | 1.00 | GRM4 (0.45) | GRM4CYP2C19GRM2GRM3CYP1A2 | |
| SCHEMBL15953786 | 1.00 | GRM4 (0.45) | GRM4CYP2C19GRM2GRM3CYP1A2 | |
| SCHEMBL2053441 | 1.00 | GRM4 (0.45) | GRM4CYP2C19GRM2GRM3CYP1A2 | |
| SCHEMBL15953683 | 1.00 | GRM4 (0.45) | GRM4CYP2C19GRM2GRM3CYP1A2 | |
| SCHEMBL2313610 | 1.00 | GRM4 (0.45) | GRM4CYP2C19GRM2GRM3CYP1A2 | |
| SCHEMBL2313607 | 1.00 | GRM4 (0.45) | GRM4CYP2C19GRM2GRM3CYP1A2 | |
| SCHEMBL2041074 | 1.00 | GRM4 (0.45) | GRM4CYP2C19GRM2GRM3CYP1A2 | |
| Hydrochloric Acid SCHEMBL28474763 | 0.98 | GRM4 (0.44) | GRM4CYP2C19GRM2GRM3CYP1A2 | |
| SCHEMBL14140688 | 0.88 | ESR2 (0.37) | KDM1ARCOR1ESR2ESR1LIG1 | |
| SCHEMBL10299842 | 0.86 | KDM1A (0.39) | LMNATSHRKDM1ARCOR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-7956195-B2 | reacting arylboronic acids with a cycloalkanone, in the presence of a rhodium catalyst or BINAP, to form a substituted arylcycloalkanone, then formin of a hydantoin, alkylation of the hydantoin, resolution, hydrolysis of the hydantoin to the amino acids and esterification of acids; chemical intermediates | ABBOTT LABORATORIES (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956195-B2 | reacting arylboronic acids with a cycloalkanone, in the presence of a rhodium catalyst or BINAP, to form a substituted arylcycloalkanone, then formin of a hydantoin, alkylation of the hydantoin, resolution, hydrolysis of the hydantoin to the amino acids and esterification of acids; chemical intermediates | ABBOTT LABORATORIES (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956195-B2 | reacting arylboronic acids with a cycloalkanone, in the presence of a rhodium catalyst or BINAP, to form a substituted arylcycloalkanone, then formin of a hydantoin, alkylation of the hydantoin, resolution, hydrolysis of the hydantoin to the amino acids and esterification of acids; chemical intermediates | ABBOTT LABORATORIES (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBVIE INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBVIE INC. | 2009-01-29 | — | — | US | disclosed |
| US-20080255367-A1 | Process for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane-carboxylates | ABBVIE INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255367-A1 | Process for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane-carboxylates | ABBVIE INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255367-A1 | Process for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane-carboxylates | ABBVIE INC. | 2008-10-16 | — | — | US | disclosed |
| WO-2008079380-A1 | PROCESS FOR THE PREPARATION AND ISOLATION OF THE INDIVIDUAL STEREOISOMERS OF 1-AMINO, 3-SUBSTITUTED PHENYLCYCLOPENTANE CARBOXYLATES | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079382-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | S1PR1, S1PR3, S1PR5 | GRM4 390/4885CYP2C19 4419/4885GRM2 454/4885 |
| US-20080255367-A1 | Process for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane-carboxylates | DDC, DNPEP, AAAS | GRM4 544/4885CYP2C19 473/4885GRM2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.